Skip to content

SW · ROG.SW · DRUG MANUFACTURERS - GENERAL

Roche Holding AG (ROG.SW) intrinsic value and stock valuation

$322.30as of 2026-11-21 · Mkt cap 256.55B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Roche Holding AG DCF and intrinsic value

InvestorsCraft values ROG.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ROG.SW’s statements →

Roche Holding AG Graham Number

Graham Number: $131.63d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Basel 4070 roche.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$61.5B+1.1% 5y CAGRd
20112025
Net income
$12.9B-2.1% 5y CAGRd
20112025
Free cash flow
$14.1B+4.2% 5y CAGRd
20112025
Total equity
$37.9B-1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$61.5B$62.4B$60.4B$65.8B$62.8B
Operating income$19.3B$13.4B$15.4B$17.5B$18.2B
Net income$12.9B$8.28B$11.5B$12.4B$13.9B
EPSd$16M$10.3M$14.3M$15.5M$16.2M
Operating cash flow$17.8B$20.1B$16.1B$17.9B$20.6B
Capital expenditure-$-3.75B-$-5.01B-$-4.65B-$-4.55B-$-4.55B
Free cash flow$14.1B$15.1B$11.4B$13.3B$16B
Total assets$100.7B$101.8B$90.5B$88.2B$92.3B
Total debt$33.2B$36.4B$30.8B$26.5B$32.6B
Net debt$27.6B$29.4B$25.4B$21.6B$25.7B
Total equity$37.9B$36.2B$33.3B$32B$28.3B
Cash and short-term investments$15.5B$17.3B$10.5B$9.77B$13B
Income statement
20252024202320222021
Revenue$61.5B$62.4B$60.4B$65.8B$62.8B
Cost of revenue$16.3B$16.3B$16.4B$17.9B$19.7B
Gross profit$45.2B$46.1B$44.1B$47.9B$43.1B
Research and development expenses$13.4B$15.3B$14.2B$15.2B$14.8B
Selling, general and administrative expenses$15.2B$14.9B$14.9B$14.2B$11.9B
Other expenses-$-2.54B$2.5B-$-392M$974M-$-854M
Operating expenses$26B$32.7B$28.7B$30.4B$25.8B
Cost and expenses$42.3B$49B$45B$48.3B$45.5B
Interest income$0.00$260M$195M$0.00$0.00
Interest expense$1.35B$1.25B$828M$608M$341M
Depreciation and amortization$3.39B$3.42B$3.46B$3.82B$4.45B
Ebitda$22.7B$16.6B$18.4B$20.8B$22.2B
Operating income$19.3B$13.4B$15.4B$17.5B$18.2B
Total other income/expenses, net-$-2.29B-$-1.62B-$-1.32B-$-1.15B-$-757M
Income before tax$17B$11.8B$14.1B$16.4B$17.4B
Income tax expense$3.17B$2.61B$1.72B$2.8B$2.46B
Net income$12.9B$8.28B$11.5B$12.4B$13.9B
Weighted average shares outstanding$796M$797M$799M$800M$850M
Weighted average diluted shares outstanding$803M$802M$804M$800M$860M
Balance sheet
20252024202320222021
Cash and short-term investments$15.5B$17.3B$10.5B$9.77B$13B
Net receivables$11.9B$13.5B$13B$13.9B$12.7B
Inventory$7.48B$7.61B$7.75B$8.61B$7.72B
Total current assets$38.7B$40B$33.4B$33.8B$35.6B
Property, plant and equipment, net$22.9B$23.7B$22.9B$24.2B$24.4B
Goodwill and intangible assets$26.8B$25.2B$24.2B$31.3B$33.7B
Long-term investments$1.13B$992M$903M$1.1B$1.2B
Total non-current assets$62B$61.8B$57B$54.3B$56.7B
Total assets$100.7B$101.8B$90.5B$88.2B$92.3B
Accounts payable$5.78B$3.98B$3.52B$3.86B$3.84B
Short-term debt$4.52B$4.26B$4.69B$4.26B$15.5B
Deferred revenue$0.00$809M$614M$601M$560M
Total current liabilities$28B$27B$24.8B$27.2B$38.4B
Long-term debt$28.7B$32.1B$26.1B$22.3B$17.1B
Deferred revenue, non-current$116M$160M$227M$254M$246M
Total non-current liabilities$34.8B$38.6B$32.4B$28.9B$25.6B
Capital lease obligations$1.56B$1.7B$1.57B$1.19B$1.35B
Total liabilities$62.8B$65.6B$57.2B$56.1B$64B
Common stock$107M$107M$107M$107M$160M
Retained earnings$48.8B$43.8B$42.3B$38.9B$34.2B
Accumulated other comprehensive income (loss)-$-15.14B-$-12.18B-$-13.14B-$-11.05B-$-9.83B
Total equity$37.9B$36.2B$33.3B$32B$28.3B
Total investments$11B$11.3B$6.04B$5.87B$7.38B
Total debt$33.2B$36.4B$30.8B$26.5B$32.6B
Net debt$27.6B$29.4B$25.4B$21.6B$25.7B
Cash flow statement
20252024202320222021
Net income$12.9B$9.19B$11.5B$12.4B$13.9B
Depreciation and amortization$0.00$3.43B$3.47B$3.82B$4.45B
Stock-based compensation$0.00$855M$830M$738M$663M
Change in working capital-$-1.66B$1.16B-$-1.11B-$-2.42B-$-994M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$17.8B$20.1B$16.1B$17.9B$20.6B
Investments in property, plant and equipment-$-5.78B-$-3.53B-$-3.74B-$-4.55B-$-4.55B
Acquisitions, net-$-2.92B-$-2.84B-$-5.49B-$-162M-$-2.29B
Net cash used for investing activities-$-8.71B-$-11.39B-$-10.64B-$-3.57B-$-6.55B
Common stock issued$0.00-$-1.13B$0.00-$-1.26B-$-1.41B
Common stock repurchased-$-987M$0.00-$-1.14B$0.00-$-18.99B
Dividends paid-$-8.39B-$-7.65B-$-7.59B-$-7.45B-$-7.77B
Net cash used for financing activities-$-10.18B-$-6.82B-$-4.24B-$-15.72B-$-12.7B
Net change in cash-$-1.39B$1.6B$385M-$-1.86B$1.12B
Cash at end of period$5.58B$6.98B$5.38B$4.99B$6.85B
Operating cash flow$17.8B$20.1B$16.1B$17.9B$20.6B
Capital expenditure-$-3.75B-$-5.01B-$-4.65B-$-4.55B-$-4.55B
Free cash flow$14.1B$15.1B$11.4B$13.3B$16B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Roche Holding AG

        Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

        CEO
        Thomas Schinecker
        Employees
        103.25K
        Beta
        0.21

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Roche Holding AG (ROG.SW)?

        InvestorsCraft does not currently publish an intrinsic value for ROG.SW. How the IC value is calculated.

        Is ROG.SW undervalued?

        InvestorsCraft does not publish an undervaluation signal for ROG.SW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.